Novavax initiated phase 1/2 clinical trial of combination vaccine for COVID-19 and seasonal influenza
On Sept. 8, 2021, Novavax announced enrollment of the first participants in a Phase 1/2 study to evaluate…
On Sept. 8, 2021, Novavax announced enrollment of the first participants in a Phase 1/2 study to evaluate…
On Sept. 1, 2021, Rigel Pharma announced the publication of results from a Phase 2 clinical trial evaluating…
On Aug. 27, 2021, The National Institutes of Health announced that it had begun a clinical trial to…
On Aug. 19, 2021, Oregon Health & Science University (OHSU) announced that it was part of a randomized,…
On Aug. 13, 2021, Rigel Pharma announced that the U.S. Food and Drug Administration (FDA) had informed the…
On Aug. 12, 2021, Innovation Pharma released information regarding the status of its randomized, double-blind, placebo-controlled Phase 2…
On Aug. 11, 2021, the National Institutes of Health (NIH) announced that one dose of a new monoclonal…
On Aug. 9, 2021, Inovio Pharma announced that it had received regulatory allowance for two clinical trials investigating…
On Aug. 3, 2021, CytoDyn announced that Brazil’s regulatory authority ANVISA (Agência Nacional de Vigilância Sanitária) has approved…
On Aug. 2, 2021, Vaxart announced that the U.S. Food and Drug Administration had cleared Vaxart’s Investigational New…
On Jul. 29, 2021, the National Institutes of Health announced it had launched a new online research tool…
On Jul. 29, 2021, Vaxart announced that it had shown for the first time in clinical trials that…
On Jul. 21, 2021, Sorrento Therapeutics announced that COVID-19 patients had been dosed in its Phase 2 efficacy…
On Jul. 15, 2021, Corvus Pharmaceuticals announced that it had discontinued its Phase 3 study of mupadolimab for…
On Jul. 6, 2021, the World Health Organization announced updated patient care guidelines to include interleukin-6 receptor blockers,…
On Jul. 1, 2021, HDT Bio announced the U.S. Food and Drug Administration had reviewed the companyï¾’s Investigational…
On Jun. 30, 2021, the National Institutes of Health announced that two U.S. Phase 1 clinical trials of…
On Jun. 30, 2021, Novavax announced the publication of results from the final analysis of a pivotal Phase…
On Jun. 29, 2021, Altimmune announced phase 1 AdCOVID clinical trial data that showed AdCOVID appeared to be…
On Jun. 23, 2021, Biogen and Eisai announced that the U.S. Food and Drug Administration (FDA) had granted…
On Jun. 17, 2021, the Biden Administration is investing more than $3 billion to accelerate the discovery, development…
On Jun. 16, 2021, RELIEF THERAPEUTICS reported that its collaboration partner, NRx Pharmaceuticals, had announced additional results from…
On Jun. 16, 2021, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced that was recruiting volunteers in the…
On Jun. 15, 2021, Oncotelic announced that, as of June 11, 2021, it discontinued enrollment in its OT-101…
On Jun. 14, 2021 Humanigen announced it had initiated a rolling review submission for Marketing Authorization (MA) by…
On Jun. 8, 2021, Merck announced it had entered into a procurement agreement with the U.S. government for…
On Jun. 3, 2021, Innovation Pharma announced that it had achieved full patient enrollment in its randomized, double-blind,…
On Jun. 1, 2021, the National Institutes of Health announced that it had started a Phase 1/2 clinical…
On May 28, 2021, Amgen announced that the U.S. Food and Drug Administration (FDA) had approved LUMAKRAS (sotorasib)…
On May 28, 2021, Humanigen announced that the company had submitted an application to the FDA requesting Emergency…